VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Jun 26, 2007 -- Inflazyme Pharmaceuticals Ltd. (Toronto:IZP.TO - News), today announced the outcome of an ongoing review of study reports (provided by Helicon Therapeutics Inc. who conducted the studies) for IPL455,903 (HT-0712), a PDE4 inhibitor discovered and patented by Inflazyme. Based on this review, Inflazyme believes that the data may support further clinical studies with IPL455,903, as well as the development of Inflazyme's other PDE4 inhibitors.
